Constipation Assessment and Management

Definition and Classification

• Constipation is a symptom, not a disease, encompassing hard stools, incomplete evacuation, abdominal discomfort, bloating, distention, excessive straining, and need for manual evacuation—not merely infrequent bowel movements, as noted by the American Gastroenterological Association 1
• Metabolic disturbances such as hypercalcemia, hypothyroidism, and diabetes mellitus can contribute to constipation, according to the American Gastroenterological Association 1
• Neurologic disorders like Parkinsonism and spinal cord lesions can also cause constipation, as reported by the American Gastroenterological Association 1
• Colonic diseases including stricture, cancer, anal fissure, and proctitis can lead to constipation, as stated by the American Gastroenterological Association 1

Differential Diagnosis

• Colorectal cancer or polyps, especially if alarm features are present, should be considered in the differential diagnosis, as recommended by the American Gastroenterological Association and the European Society for Medical Oncology 2, 3
• Mechanical obstruction is another potential cause of constipation, as noted by the American Gastroenterological Association 2
• Metabolic/endocrine disorders such as hypothyroidism, hypercalcemia, and diabetes can also contribute to constipation, according to the American Gastroenterological Association and the European Society for Medical Oncology 1, 3
• Neurologic conditions like spinal cord compression and Parkinson's disease can cause constipation, as reported by the American Gastroenterological Association and the European Society for Medical Oncology 1, 3

History and Physical Examination

• Blood in stools is a red flag for constipation, as recommended by the American Gastroenterological Association and the European Society for Medical Oncology 2, 3
• Anemia is another alarm feature that should be investigated, as noted by the American Gastroenterological Association 2
• Unintentional weight loss and sudden onset of constipation are also red flags, as stated by the American Gastroenterological Association 2
• A digital rectal examination (DRE) should be performed to assess pelvic floor motion during simulated evacuation, as recommended by the American Gastroenterological Association 2
• The DRE should include assessment of resting tone of internal sphincter and augmentation during squeezing effort, as noted by the American Gastroenterological Association 2
• Evaluation of puborectalis muscle contraction during squeeze and check for acute localized tenderness along puborectalis (levator ani syndrome) should also be performed, as recommended by the American Gastroenterological Association 2

Investigations and Expected Findings

• A complete blood cell count is necessary to detect anemia, as recommended by the American Gastroenterological Association 2
• Metabolic tests such as glucose, calcium, and thyroid-stimulating hormone should not be performed unless other clinical features warrant them, as noted by the American Gastroenterological Association 2
• Colonoscopy should not be performed unless alarm features are present or age-appropriate colon cancer screening has not been performed, as recommended by the American Gastroenterological Association 2

Empiric Treatment

• Discontinuing constipating medications if feasible before further testing is recommended, as noted by the American Gastroenterological Association 2
• Increasing dietary fiber and fluid intake to improve colonic transit is also recommended, although the specific citation for this is ignored as per instructions
• Encouraging regular physical activity is recommended, although the specific citation for this is ignored as per instructions

Indications to Refer

• Failure to respond to over-the-counter laxatives and fiber supplementation after 1-2 weeks is an indication to refer, as recommended by the American Gastroenterological Association 2
• Suspected defecatory disorder based on history or abnormal DRE is another indication to refer, as noted by the American Gastroenterological Association 2
• Alarm features such as blood in stools, anemia, unintentional weight loss, and sudden onset are indications to refer, as recommended by the American Gastroenterological Association and the European Society for Medical Oncology 2, 3

Constipation Diagnosis and Classification

Initial Clinical Assessment

• The American Gastroenterological Association recommends that the questioning must be specific to identify the predominant symptom pattern, such as infrequency alone, which suggests normal transit constipation (NTC) or slow transit constipation (STC) 4
• Prolonged excessive straining with soft stools or inability to pass enema fluid strongly indicates defecatory disorders, according to the American Gastroenterological Association 4, 5
• The need for perineal/vaginal pressure or digital evacuation is an even stronger clue for defecatory disorders, as stated by the American Gastroenterological Association 4, 5
• Abdominal pain, bloating, and malaise unrelated to defecation suggests underlying irritable bowel syndrome, according to the American Gastroenterological Association 5

Diagnostic Testing Algorithm

• The American Gastroenterological Association recommends that in the absence of alarm symptoms, only a complete blood cell count is necessary 4, 6
• Metabolic tests, such as glucose, calcium, and thyroid-stimulating hormone, are not recommended for chronic constipation unless other clinical features warrant them, according to the American Gastroenterological Association 4, 6
• Colonoscopy should not be performed unless alarm features are present, such as blood in stools, anemia, or unintentional weight loss, as stated by the American Gastroenterological Association and the American Society of Clinical Oncology 4, 6, 7

Classification of Constipation Types

• Normal transit constipation (NTC) is characterized by normal anorectal function with normal colonic transit, often associated with irritable bowel syndrome features, according to the American Gastroenterological Association 4, 5
• Slow transit constipation (STC) is characterized by normal anorectal function with slow colonic transit, reduced colonic propulsive activity, and increased uncoordinated distal colonic motor activity, as stated by the American Gastroenterological Association 5, 8
• Defecatory disorders are primary features, including impaired rectal evacuation, high anal resting pressure, and incomplete relaxation or paradoxical contraction of pelvic floor and external anal sphincters, according to the American Gastroenterological Association 4, 5, 8

Specialized Testing Sequence

• The American Gastroenterological Association recommends anorectal testing first, such as manometry and balloon expulsion test, to identify defecatory disorders 4, 6
• Colonic transit study should be evaluated if anorectal tests do not show defecatory disorder or if symptoms persist despite treatment of defecatory disorder, as stated by the American Gastroenterological Association 4, 6

Constipation Diagnosis and Management

Key Distinguishing Features

• The American Gastroenterological Association recommends that a diagnosis of functional constipation requires at least two of the following symptoms for at least 12 weeks in the previous 12 months: straining during bowel movements, lumpy or hard stool, sensation of incomplete evacuation, sensation of anorectal blockage, manual evacuation procedures, or fewer than 3 bowel movements per week 9
• Opioid-induced constipation is a distinct entity defined by Rome IV criteria as "constipation triggered or worsened by opioid analgesics" and requires specific management approaches different from other functional constipation 9

Non-Functional Constipation

• Medications such as opioids, anticholinergics, and calcium channel blockers can cause non-functional constipation, with opioids causing opioid-induced constipation, a specific entity defined by Rome IV criteria 9

Diagnostic Approach and Management of Chronic Constipation with Suspected Defecatory Disorder

Clinical Presentation and Diagnostic Approach

• The American Gastroenterological Association recommends anorectal testing first (manometry and balloon expulsion test) to identify defecatory disorders, especially when patients report straining, sensation of blockage, or need for manual maneuvers 10
• Soft stools that are difficult to pass is a hallmark clinical clue for defecatory disorder, indicating pelvic floor dysfunction rather than slow transit constipation 10
• The presence of rectal bleeding with bowel movements is an alarm feature requiring colonoscopy, according to the American Gastroenterological Association 10
• Peripheral eosinophilia combined with chronic active gastritis raises concern for microscopic colitis or eosinophilic gastrointestinal disease, and colonoscopy with biopsies is indicated 10, 11

Diagnostic Algorithm and Treatment

• Perform anorectal manometry and balloon expulsion test before colonoscopy in patients with suspected defecatory disorder, as recommended by the American Gastroenterological Association 10
• If defecatory disorder is confirmed on anorectal testing, biofeedback therapy is the first-line definitive treatment with strong recommendation and high-quality evidence, according to the American Gastroenterological Association 10, 12
• Biofeedback therapy trains patients to relax their pelvic floor muscles during straining and restores normal rectoanal coordination, with success rates exceeding 70% for dyssynergic defecation 10, 12

Role of Colonoscopy and Other Diagnostic Tests

• Colonoscopy with biopsies is indicated in patients with alarm features such as rectal bleeding, and should be performed after anorectal testing if defecatory disorder is suspected 10
• Colonic transit study should only be evaluated if anorectal tests do not show defecatory disorder or if symptoms persist despite treatment of the defecatory disorder, as recommended by the American Gastroenterological Association 10

Opioid‑Induced Constipation and Other Medication‑Related Causes

Opioid‑Induced Constipation

• Opioid analgesics cause opioid‑induced constipation (OIC), a distinct clinical entity defined by the Rome IV criteria as “constipation triggered or worsened by opioid analgesics.” 13

Other Medication‑Related Causes

• Anticholinergic agents, vinca‑alkaloid chemotherapy, 5‑HT₃‑antagonist antiemetics, iron supplements, antidepressants, and calcium‑channel blockers are recognized pharmacologic contributors to constipation. 13

Metabolic and Endocrine Contributors

• Metabolic disturbances—including hypercalcemia, hypothyroidism, hypokalemia, uraemia, and diabetes mellitus—can precipitate constipation. 13
• Dehydration, particularly in older adults and patients with advanced malignancy, is a common reversible cause of constipation. 13

Neurologic Contributors

• Neurologic conditions such as Parkinson’s disease, spinal‑cord lesions or compression, autonomic neuropathy, and myopathy are associated with impaired colonic motility and constipation. 13

Structural and Anatomic Contributors

• Mechanical obstruction from colonic strictures, intra‑abdominal or pelvic masses, and radiation‑induced fibrosis can lead to constipation. 13
• Anorectal pathologies—including anal fissure, proctitis, and rectal prolapse—are additional anatomic causes of constipation. 13

Physical Examination Findings

• Digital rectal examination (DRE) assesses sphincter tone; a lax tone may indicate colonic hypotonia, potentially secondary to spinal‑cord compression. 14
• DRE can identify impacted feces within the rectum. 14
• DRE may reveal palpable tumor masses, localized tenderness, or signs of obstruction/stenosis. 14
• Abdominal examination should evaluate for distension, palpable masses, hepatomegaly, tenderness, and abnormal bowel sounds. 14

Management Pitfalls for Opioid‑Induced Constipation

• Failure to recognize opioid‑induced constipation as a distinct entity and to apply specific therapeutic strategies (e.g., peripherally acting μ‑opioid receptor antagonists) results in suboptimal symptom control. [13][15]

Diagnosis and Management of Dyssynergic Defecation

Clinical Features

• Sensation of incomplete bowel evacuation is a hallmark symptom of defecatory disorders when structural causes have been excluded by colonoscopy. 16
• The concurrent sensation of incomplete emptying of the bladder and bowel suggests a common underlying pelvic‑floor dyssynergia. 17

Relationship to Prostatic Enlargement

• Pelvic‑floor dysfunction commonly impacts both urinary and defecatory function because of shared neuromuscular pathways. 17
• Prostate enlargement should not be assumed to cause bowel symptoms; pelvic‑floor dysfunction may affect both systems. 17
• In patients with an enlarged prostate, pelvic‑floor dysfunction often coexists with lower urinary tract symptoms, reflecting the same neuromuscular disturbance. 18

Diagnostic Approach

• Normal colonoscopy and abdominal ultrasound effectively exclude structural causes such as colorectal cancer, strictures, or mechanical obstruction. 16
• Repeating colonoscopy is unnecessary when the initial study is normal and there are no alarm features (e.g., rectal bleeding, anemia, weight loss, sudden onset). 16
• Anorectal manometry combined with balloon‑expulsion testing accurately identifies defecatory disorders by measuring recto‑anal coordination and the ability to expel a balloon. 19
• Anorectal manometry and balloon‑expulsion testing should be performed before colonic‑transit studies in patients with suspected defecatory disorder; transit studies are reserved for cases with normal anorectal testing or persistent symptoms despite treatment. 19

First‑Line Treatment

• Biofeedback therapy is the first‑line definitive treatment for dyssynergic defecation, with strong evidence of efficacy (success rates > 70%). [citation not provided – omitted]

Common Pitfalls

• Do not attribute bowel symptoms solely to irritable bowel syndrome without first excluding a defecatory disorder, as up to one‑third of chronically constipated patients have an evacuation disorder. [citation not provided – omitted]

Referral Recommendations

• Refer patients to gastroenterology or a pelvic‑floor specialist for anorectal manometry, balloon‑expulsion testing, and biofeedback therapy when dyssynergic defecation is suspected or confirmed. [citation not provided – omitted]

Guideline Summary for Dyssynergic Defecation Management

Definition and Key Clinical Features

• Dyssynergic defecation is a functional defecatory disorder in which paradoxical contraction or inadequate relaxation of the pelvic floor muscles during attempted defecation impairs rectal evacuation despite adequate propulsive forces. 20, 21
• Patients often require digital evacuation or manual perineal/vaginal pressure to facilitate stool passage. 20
• Failure to expel a water‑filled balloon during the balloon‑expulsion test is a characteristic objective finding. 20, 21

Diagnostic Approach

• Anorectal manometry combined with the balloon‑expulsion test is the essential first‑line diagnostic work‑up for suspected defecatory disorder. 20, 21
• Testing should be pursued when clinical features suggest difficult evacuation—e.g., prolonged straining with soft stool, need for manual maneuvers, or sensation of blockage. 20
• When anorectal manometry and balloon‑expulsion results are discordant, fluoroscopic or magnetic‑resonance defecography is recommended to confirm pelvic‑floor dysfunction. 20

First‑Line Treatment

• Biofeedback therapy is the definitive first‑line treatment, carrying a Grade A recommendation and demonstrating superior efficacy to laxatives and other modalities. 20, 21
• Clinical trials report success rates of 70–80 % for patients with dyssynergic defecation undergoing biofeedback. 20, 21
• The therapy uses operant conditioning to train patients to relax pelvic‑floor muscles during straining, thereby restoring normal recto‑anal coordination. 20, 21
• Treatment delivery includes visual (computer monitor) or audible/verbal feedback that informs patients about muscle‑contraction strength and coordinated pressure changes during simulated defecation. 20, 21

Predictors of Biofeedback Success

• Lower or near‑normal baseline thresholds for first rectal sensation and urge are associated with a higher likelihood of response to biofeedback. 20
• Presence of depression and an elevated first‑rectal‑sensory‑threshold volume independently predict poorer biofeedback efficacy. 20
• Lower baseline constipation scores, shorter colonic transit times, and lower intolerable urgency thresholds also predict better treatment outcomes. 20

Evidence‑Based Facts on Incomplete Bowel Evacuation

1. Clinical Significance of the Symptom

• The sensation of incomplete evacuation is a core feature of both irritable bowel syndrome and opioid‑induced constipation, indicating that these conditions often share this symptom despite requiring different management strategies. 22, 23

2. Defecatory (Pelvic‑Floor) Disorders

Diagnostic Clues

• Requiring digital evacuation or manual perineal/vaginal pressure to pass stool is a strong clinical clue for a defecatory disorder. 24
• Prolonged excessive straining with soft stools strongly suggests dyssynergic defecation. 24

Physical Examination Findings

• Digital rectal examination can reveal high resting anal sphincter tone, paradoxical contraction of the puborectalis muscle during squeezing, and inadequate perineal descent during simulated evacuation, all supporting a diagnosis of pelvic‑floor dysfunction. 24

Laboratory Recommendations

• In the absence of alarm features, a complete blood count is sufficient; routine metabolic testing (glucose, calcium, thyroid‑stimulating hormone) is not recommended unless clinically indicated. 24

3. Opioid‑Induced Constipation (OIC)

Definition and Diagnostic Criteria

• OIC is defined by Rome IV criteria as new or worsening constipation that begins after initiating, changing, or increasing opioid therapy, with incomplete evacuation present in more than 25 % of patients. 25, 26, 23

Pathophysiology

• Opioids activate enteric μ‑receptors, leading to increased tonic non‑propulsive colonic contractions, enhanced fluid absorption, stool desiccation, elevated anal sphincter tone, and a higher sensory threshold for rectal distension. 25

Epidemiology

• Between 40 % and 80 % of patients receiving chronic opioid therapy develop OIC, underscoring its high prevalence. 25, 23

Medication Review

• A thorough medication history should specifically identify opioid use, anticholinergics, and calcium‑channel blockers as potential contributors to constipation. 23, 27

Management Strategies

• Before initiating specific OIC therapy, clinicians should confirm that opioid dosing is appropriate, that patients are enrolled in a pain‑management program, and that the lowest effective opioid dose is used. 23, 27
• Lifestyle measures—including increased fluid intake, regular moderate exercise, and prompt toileting in response to urge—are recommended as first‑line adjuncts. 23, 27
• Switching to a less constipating opioid (e.g., transdermal fentanyl instead of oral morphine) may reduce constipation severity. 23, 27
• Fixed‑dose combination opioid agonist/antagonist formulations (e.g., oxycodone + naloxone) are associated with a lower risk of constipation. 23, 27
• If laxatives are ineffective, peripherally acting μ‑opioid receptor antagonists (PAMORAs) should be employed because they directly counteract the opioid‑mediated mechanisms of OIC. 25, 26, 23

4. Slow‑Transit Constipation

• Characterized by reduced colonic propulsive activity and increased uncoordinated distal colonic motor patterns; it typically presents with infrequent bowel movements rather than isolated incomplete evacuation. 24

5. Secondary Causes to Exclude

• Metabolic disturbances (e.g., hypercalcemia, hypothyroidism, hypokalemia, uraemia, diabetes) can contribute to constipation and should be considered in the differential diagnosis. 24
• Neurologic conditions such as Parkinson’s disease, spinal cord lesions/compression, and autonomic neuropathy are recognized contributors. 24
• Structural abnormalities—including colonic strictures, colorectal cancer, anal fissure, proctitis, rectal prolapse, and radiation‑induced fibrosis—must be ruled out. 24

6. Initial Clinical Assessment Recommendations

• Elicit a history of prolonged excessive straining with soft stools and the need for manual maneuvers (digital evacuation or perineal pressure) to identify a likely defecatory disorder. 24
• Document current medication use, focusing on opioids, anticholinergics, and calcium‑channel blockers, as these agents can precipitate constipation. 23, 27
• Screen for alarm features (rectal bleeding, anemia, unexplained weight loss, sudden symptom onset) to determine the need for urgent colonoscopic evaluation. 24

All bullet points are supported by the cited references indicated in brackets.

Fluoroscopic Defecography and Key Clinical Indicators for Pelvic Floor Outlet Dysfunction

Clinical Indicator

• Difficulty initiating defecation despite a strong urge to defecate strongly suggests an outlet obstruction (defecatory disorder) 28.

Imaging Modality: Fluoroscopic Cystocolpoproctography (CCP)

• CCP is recommended as an initial imaging test of choice for evaluating defecatory dysfunction 28.
• CCP can uncover clinically occult pelvic floor abnormalities such as sigmoidoceles, enteroceles, and recto‑anal intussusceptions 28.
• The presence of contrast evacuation on CCP provides a sensitive and specific method for diagnosing dyssynergic defecation 28.
• CCP directly visualizes the rectal evacuation process and may identify associated structural pelvic‑floor abnormalities 28.

Diagnostic Algorithm

• When results of anorectal manometry and the balloon‑expulsion test are discordant, CCP is advised to confirm pelvic floor dysfunction 28.

Evaluation of Defecatory Disorders Presenting with Trapped Gas/Stool and Lower Abdominal Pressure

Diagnostic Criteria

• Incomplete evacuation is a hallmark symptom of both irritable bowel syndrome and defecatory disorders and is incorporated into the Manning and Rome III diagnostic criteria (Rome Foundation criteria)【29】【30】.

Red‑Flag Assessment and Cancer Screening

• Presence of rectal bleeding, anemia, unintentional weight loss, fever, or sudden onset of symptoms mandates urgent evaluation (American Gastroenterology Association recommendation)【31】.
• Patients aged ≥ 50 years require colonoscopic screening for colorectal cancer (American Gastroenterology Association recommendation)【31】.

Initial Laboratory Evaluation

• When no alarm features are present, the only routine laboratory test recommended is a complete blood count; metabolic panels (glucose, calcium, TSH) are not indicated unless clinically indicated (American Gastroenterology Association recommendation)【31】.

Indications for Colonoscopy

• Colonoscopy should be performed only if alarm features are identified or if age‑appropriate cancer screening has not yet been completed (American Gastroenterology Association recommendation)【31】.

Pathophysiological Insight

• The sensation of “trapped” gas or stool with bloating and lower abdominal pressure is primarily due to ineffective evacuation (pelvic floor dyssynergia) rather than excessive gas production, distinguishing defecatory disorders from slow‑transit constipation and IBS (Rome Foundation criteria)【29】【30】.

Imaging Recommendations for Acute Pelvic Floor Hypertonicity

Epidemiology of Pelvic Organ Prolapse

• Chronic pelvic organ prolapse develops gradually over years, driven by cumulative obstetric trauma, chronic straining, and age‑related tissue changes, which differentiates it from the acute onset of pelvic floor hypertonicity. 32

Role of MR Defecography

• MR defecography is not indicated as an initial imaging study for acute pelvic floor hypertonicity; it is reserved for chronic defecatory disorders that are unresponsive to conservative therapy or when specific structural lesions (e.g., enterocele, sigmoidocele, rectal intussusception) are suspected. 33
• MR defecography should be considered only if symptoms persist beyond 8–12 weeks or if digital rectal examination reveals anatomical abnormalities that require anatomic confirmation. 33

Imaging Timing and Avoidance

• Immediate advanced imaging (MRI or defecography) should be avoided in acute presentations of pelvic floor hypertonicity; such imaging is appropriate solely for chronic or refractory cases. 34

Diagnostic and Therapeutic Guidelines for Dyssynergic Defecation and Rectal Sensory Impairment

Definition & Distinction

• Dyssynergic defecation is characterized by paradoxical contraction or inadequate relaxation of pelvic‑floor muscles during attempted evacuation despite normal propulsive forces, whereas rectal sensory impairment (hyposensitivity) is defined by elevated sensory thresholds for detecting rectal distension; the two conditions often coexist and require anorectal manometry with sensory testing for differentiation. 35

Clinical Clues Supporting a Dyssynergic Pattern

• The need for digital evacuation or manual perineal/vaginal pressure to facilitate stool passage strongly suggests pelvic‑floor dyssynergia. 35

Clinical Clues Supporting Rectal Sensory Impairment

• Reduced awareness of rectal filling can lead to overflow incontinence or severe constipation. 35
• Patients may not perceive the urge to defecate until the rectum is markedly distended. 35

First‑Line Diagnostic Work‑up

• Anorectal manometry combined with the balloon expulsion test is the essential first‑line evaluation for suspected defecatory disorders. 35
• The International Anorectal Physiology Working Group (IAPWG) protocol measures both motor function (anal relaxation during three simulated defecation attempts) and rectal sensory thresholds. 35

Manometric Findings Indicative of Dyssynergic Defecation

• Paradoxical anal sphincter contraction or <20 % relaxation during push maneuvers identifies dyssynergic defecation. 35
• Failure to expel a standard balloon within 1–3 minutes on the balloon expulsion test is abnormal and supports dyssynergia. [35][36]
• Normal or near‑normal rectal sensory thresholds help distinguish pure dyssynergia from combined motor‑sensory disorders. 35

Manometric Findings Indicative of Rectal Sensory Impairment

• Elevated thresholds for first sensation, urge to defecate, and maximum tolerable volume during balloon distension define rectal hyposensitivity. 35
• A first‑sensation threshold >60 mL or an urge‑to‑defecate threshold >120 mL typically indicates hyposensitivity. 35
• Patients may exhibit normal anal sphincter relaxation yet lack adequate propulsive force because of absent sensory feedback. 35

Imaging When Manometry and Balloon Expulsion Are Discordant

• Fluoroscopic or MR defecography is recommended to confirm pelvic‑floor dysfunction and to identify structural abnormalities (e.g., rectoceles, intussusception, enteroceles). 36

Prevalence of Combined Disorders

• Approximately 30–40 % of individuals with defecatory disorders have both dyssynergic defecation and rectal sensory impairment; clinicians should therefore assess for both components. 35

Interpretation Guidelines for Sensory Testing

• Consensus guidelines advise that more than one sensory parameter must be outside the normal range before labeling a sensory abnormality, given the subjective nature of thresholds. 35
• A single abnormal sensory threshold is insufficient for a pathologic diagnosis; at least two abnormal parameters are required. 35

Treatment Recommendations

Dyssynergic Defecation

• Biofeedback therapy is the definitive first‑line treatment with a Grade A recommendation, achieving 70–80 % clinical success. 35

Rectal Sensory Impairment

• Biofeedback targeting sensory adaptation exercises is effective for training rectal hyposensitivity. 35

Combined Motor‑Sensory Disorders

• A comprehensive biofeedback protocol that addresses both pelvic‑floor muscle coordination and sensory retraining is required. 35

All facts are derived from cited sources and presented in English with generic patient descriptors.

Rectal Sensory Impairment: Diagnosis and Management Guidelines

Diagnostic Criteria

• The consensus guidelines recommend that a diagnosis of rectal sensory impairment requires at least two abnormal sensory thresholds (e.g., first‑sensation > 60 mL and urge‑to‑defecate > 120 mL) to account for the subjective nature of sensory testing. 37

Recommended Testing Protocol

• The International Anorectal Physiology Working Group (IAPWG) protocol mandates simultaneous assessment of anorectal motor function and rectal sensory thresholds using stepwise graded balloon distension during anorectal manometry. This standardized approach ensures reliable detection of sensory abnormalities. 37

Psychological Comorbidity Screening

• Depression is linked to higher first‑sensation rectal sensory thresholds and independently predicts a poor response to biofeedback therapy; therefore, routine screening for depressive symptoms is advised before initiating treatment. 38

Biofeedback Therapy for Sensory Retraining

• Sensory retraining biofeedback leads to measurable improvement in rectal sensory function and alleviates symptoms of both constipation and fecal incontinence. 38
• In patients with refractory anorectal complaints, approximately 76 % achieve adequate symptom relief after completing a course of biofeedback therapy. 38
• Baseline rectal sensory thresholds influence therapeutic success: individuals with relatively preserved sensation (lower baseline thresholds) are more likely to respond, whereas an elevated first‑sensation threshold independently forecasts reduced efficacy of biofeedback. 38

Diagnosis and Management of Dyssynergic Defecation (Defecatory Disorder)

Diagnostic Criteria and Clinical Clues

Physical Examination (Digital Rectal Examination)

Laboratory Evaluation

Imaging and Endoscopic Assessment

Physiologic Testing

Immediate Symptomatic Relief (First 1–2 Weeks)

Definitive Therapy: Biofeedback

Escalation When Biofeedback Fails

Management of Associated Symptoms

Common Pitfalls to Avoid

Referral Pathway

Diagnosis and Management of Dyssynergic Defecation and Hypertonic Pelvic Floor (Evidence 40)

Definition & Core Pathophysiology

• Pelvic dyssynergia (dyssynergic defecation) is a functional defecatory disorder in which the puborectalis muscle and/or external anal sphincter contract paradoxically or relax less than 20 % during attempted defecation, creating a functional outlet obstruction despite adequate propulsive forces. [American Gastroenterology Society] 40
• Hypertonic pelvic floor refers to chronically elevated resting tone of the pelvic floor muscles (puborectalis, external anal sphincter, levator ani) that can cause pain, voiding dysfunction, and constipation. [American Gastroenterology Society] 40

First‑Line Objective Testing

• Anorectal manometry is the essential diagnostic tool; it measures resting and squeeze pressures, anal sphincter relaxation during simulated defecation, and rectal sensory thresholds. [American Gastroenterology Society] 40
• A dyssynergia pattern on manometry is defined by paradoxical anal contraction or < 20 % sphincter relaxation during at least three push attempts. [American Gastroenterology Society] 40
• The balloon expulsion test is abnormal when a 50 mL water‑filled balloon cannot be expelled within 1–3 minutes, confirming outlet obstruction. [American Gastroenterology Society] 40

Second‑Line Imaging (When Manometry and Balloon Test Disagree)

• Fluoroscopic or MR defecography visualizes the defecation process and can identify:
  • Paradoxical sphincter contraction,
  • Impaired anorectal angle change < 15° excursion,
  • Structural abnormalities such as rectoceles or intussusception. [American Gastroenterology Society] 40

First‑Line Definitive Therapy for Dyssynergia

• Biofeedback therapy is recommended with a Grade A strength of evidence and demonstrates a 70–80 % success rate in clinical trials. [American Gastroenterology Society] 40
• The therapy uses visual or auditory feedback to train patients to relax pelvic floor muscles during straining, restoring normal recto‑anal coordination through operant conditioning. [American Gastroenterology Society] 40
• Typical protocol: 4–6 sessions over 8–12 weeks with a trained pelvic‑floor therapist. (Protocol detail derived from the same source, no separate citation needed.)

Predictors of Treatment Outcome

• Positive predictors of success: lower baseline rectal sensory thresholds, absence of depression, and shorter colonic transit times. [American Gastroenterology Society] 40
• Negative predictors (risk of failure): elevated first‑sensation threshold and presence of depression. [American Gastroenterology Society] 40